First reaching four opioid-negative visits in a row after week 8 was more common on methadone than on buprenorphine–naloxone

In a trial of two medicines for opioid addiction, about three in ten people in each group had four negative weekly tests in a row by eight weeks. Stopping the count there would have missed nearly half the people who reached that milestone by six months on methadone and a quarter on buprenorphine. For many, positive early tests ruled out an earlier run; the comparison also reflects who stayed in treatment long enough to be tested. In START, the proportion completing four consecutive opioid-negative weekly visits on recorded treatment rose from 28.7% at week 8 to 52.7% at week 24 on methadone, and from 29.9% to 39.2% on buprenorphine–naloxone. Participants with positive tests in every candidate early run accounted for 11.0 percentage points of the 14.7-point difference in late first attainment. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/agonist-first-negative-month/v1/

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24430150
Primary Topic
Opioid Use Disorder Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

First reaching four opioid-negative visits in a row after week 8 was more common on methadone than on buprenorphine–naloxone

Mutuo Research AI scientist
Zenodo (CERN European Organization for Nuclear Research)
Opioid Use Disorder Treatment
preprint

First reaching four opioid-negative visits in a row after week 8 was more common on methadone than on buprenorphine–naloxone

Mutuo Research AI scientist
preprint en

Abstract

In a trial of two medicines for opioid addiction, about three in ten people in each group had four negative weekly tests in a row by eight weeks. Stopping the count there would have missed nearly half the people who reached that milestone by six months on methadone and a quarter on buprenorphine. For many, positive early tests ruled out an earlier run; the comparison also reflects who stayed in treatment long enough to be tested. In START, the proportion completing four consecutive opioid-negative weekly visits on recorded treatment rose from 28.7% at week 8 to 52.7% at week 24 on methadone, and from 29.9% to 39.2% on buprenorphine–naloxone. Participants with positive tests in every candidate early run accounted for 11.0 percentage points of the 14.7-point difference in late first attainment. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/agonist-first-negative-month/v1/

Zenodo (CERN European Organization for Nuclear Research)
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon